At a glance
- Common name: Serratiopeptidase (serrapeptase)
- Activity: 2,200 U/mg
- Origin: Fermentation of Serratia species
- EC number: 3.4.24.40
- Form: Enteric-coatable powder
- Item Code: 6756
What SerraSure™ Is
Serratiopeptidase is a metalloprotease enzyme of approximately 45–60 kDa with a zinc atom at its active site, belonging to the serralysin family (peptidase M10B). The enzyme was first isolated from bacteria found in the silkworm (Bombyx mori) intestine — where it enabled the emerging moth to dissolve its cocoon — and is now produced commercially by purification from culture of Serratia species under controlled fermentation. SerraSure™ is supplied as a finished enzyme powder standardized to a defined activity level.
Why 2,200 U/mg
Serratiopeptidase is sold to formulators at a wide range of activities, typically expressed in units per milligram (U/mg). Higher specific activity allows formulators to deliver a target activity at lower mg-per-dose, which simplifies capsule and tablet design and reduces excipient burden. SerraSure™ at 2,200 U/mg sits in the high-activity range commonly specified by experienced systemic-enzyme brands. Lower activity grades are available on request.
Mechanism
Serratiopeptidase is a proteolytic enzyme — it cleaves peptide bonds in proteins. In oral systemic-enzyme applications, it has been studied for its activity on fibrin-related proteins, its interaction with bradykinin and histamine pathways, and its capacity to hydrolyze proteinaceous debris associated with inflammatory exudates. Because the enzyme is acid-sensitive, oral SerraSure™ is generally formulated with enteric coating to enable delivery past gastric acid.
Why Formulators Choose SerraSure™
- High specific activity (2,200 U/mg) enables compact dose forms.
- Stable powder suited for enteric-coated tablets and DRcaps®-style capsules.
- Supplied through GCI’s long-standing fermentation-source network.
- Request the current activity assay and lot-specific certificate of analysis.
Where SerraSure™ Fits
Dosage formats: enteric-coated tablets, enteric-coated capsules (DRcaps® or equivalent), softgels with enteric protection.
Industries served: dietary supplements, sports nutrition.
Technical Specifications
Reference values below are drawn from GCI’s product documentation. Request the current specification and lot-specific certificate of analysis before purchase.
| Detail | Information |
|---|---|
| Item Code | 6756 |
| Common Name | Serratiopeptidase (serrapeptase) |
| EC Number | 3.4.24.40 |
| Activity | 2,200 U/mg (lower grades available on request) |
| Source | Fermentation of Serratia spp. |
| Appearance | Grayish white to light brown hygroscopic powder |
| Solubility | Water-soluble; acid-sensitive (recommend enteric coating) |
| Particle size | 100% through 40 mesh |
| Loss on drying | ≤7.0% w/w |
| Microbiology | Aerobic plate count ≤10,000 cfu/g; yeast and mold ≤100 cfu/g; E. coli absent/25 g; Salmonella absent |
| Origin | India |
| Shelf life | 5 years; store in a well-closed container away from heat and moisture |
For test method, heavy metals, allergens, gmo status, request the current product documentation.
Ordering Information
| Detail | Information |
|---|---|
| Standard packaging | Confirm the available pack size with your quote |
| MOQ | Quoted for the selected ingredient and order quantity |
| Lead time | Request current availability and delivery timing |
| Sample availability | Yes |
Quality, Compliance & Certifications
Request current certificates and product statements for the selected grade; certification availability is subject to verification.
- Distributed under cGMP and the GCI Sure™ program.
- Request the current specification and lot-specific certificate of analysis.
Often Formulated With
- Other systemic enzymes — bromelain, nattokinase, papain, lipase.
- Curcumin, boswellia, omega-3 — in joint and post-exercise stacks.
Resources
- SerraSure™ specification — request through the technical documents form
- Current COA — request via form
- Dr. Koz’s Corner: serratiopeptidase and biofilm series
Bring SerraSure™ Into Your Next Formulation
These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent disease. SerraSure™ is a trademark of GCI Nutrients, Inc.
Research & references
Historical references carried forward from the ingredient microsite. Research on another preparation or formulation does not establish the performance of this GCI ingredient.
- Mazzone A, et al. Evaluation of serratia peptidase in acute or chronic inflammation of otorhinolaryngology pathology: a multicentre, double-blind, randomized trial versus placebo. J Int Med Res.; 1990; 18 (5); 379-88.
- Tachibana M, et al. A muti-centre, double-blind study of serrapeptase versus placebo in post-antrotomy buccal swelling. Pharmatherapeutica; 1984; 3(8); 526-30.
- Panagariya A, Sharma AK. A preliminary trial of serratiopeptidase in patients with carpal tunnel syndrome. J Assoc Physicians India; 1999; 47 (12); 1170-1172.
- Kee WH, et al. The treatment of breast engorgement with Serrapeptase (Danzen): a randomized double-blind controlled trial. Singapore Med J.; 1989 30 (1); 48-54.
- Sasaki S, et al. Serrapeptase-induced lung injury manifesting as acute eosiniphilic pneumonia. Nihon Kokyuki Gakkai Zasshi. 2000; 38 (7); 540-4.